October 10 - 12, 2018
The Ritz-Carlton, Laguna Niguel, CA
Day Two Thursday, October 11, 2018: New Opportunities & Emerging Trends in Pharma Deal-making
Pre-Event Networking Tuesday, October 9, 2018 Day One Wednesday, October 10, 2018: The BioPharma Partnering Landscape Day Two Thursday, October 11, 2018: New Opportunities & Emerging Trends in Pharma Deal-making Day Three Friday, October 12, 2018: Deals of the Future: Final Networking & Partnering Opportunities
7:30 am - 8:30 am Breakfast & Registration
7:30 am - 8:30 am Breakfast Boardroom: Diversity & Inclusion in Biopharma Leadership
Please, join us for an intimate conversation about diversity and inclusion in the biopharma industry. It is no longer a debate that organizations with representative and diverse leadership deliver higher performance. But how to be inclusive remains a challenge. Come discuss practical, tactical steps to increase the representation of women and minorities across business ranks, the C-Suite, and the board room. Share what has worked (and what hasn’t) in your organization and co-create best practices. This breakfast discussion is open to all, but limited to 20 participants. Sign-up form will be shared two weeks prior to the event.
8:35 am - 8:50 am Chairperson’s Opening Address
8:50 am - 9:20 am Keynote Panel: The Colliding Worlds of High Technology & Life SciencesDr. John Baldoni - Senior Vice President GlaxoSmithKline Luba Greenwood - Strategic Business Development & Corporate Ventures Verily Alice Zhang - CEO & Co-Founder Verge Genomics
With an exciting year behind us in terms of life-science and high technology collaborations, our panelists will discuss:
•What are the benefits of the recent partnerships we’ve seen bringing together technology and life science?
•What other opportunities lie for companies to push forward drug development with the help of high tech?
•What can we expect over the next year in terms of high-tech involvement in biopharma?
Dr. John BaldoniSenior Vice President
Luba GreenwoodStrategic Business Development & Corporate Ventures
Alice ZhangCEO & Co-Founder
9:20 am - 9:50 am Deal Chat: The Story Behind a $7 Billion DealMichael Attar - Executive Director, Business Development Celgene John Hood - Founder & CEO Impact Biosciences, a Celgene subsidiary
John Hood and Michael Attar will share the story behind $7 billion deal that gave Impact Biosciences the opportunity to keep developing a potential treatment for myelofibrosis.
Michael AttarExecutive Director, Business Development
John HoodFounder & CEO
Impact Biosciences, a Celgene subsidiary
9:50 am - 10:05 am Biotech Spotlight
10:05 am - 10:20 am Biotech Spotlight
10:20 am - 10:50 am Morning Refreshment Break
10:50 am - 11:20 am Panel: Gene & Cell Celebrations: What Can We Expect Next?Brinda Balakrishnan - GVP, Corporate & Business Development BioMarin Jim Bowen - Executive Director, Corporate Alliances, Penn Center for Innovation University of Pennsylvania Nina Kjellson - General Partner Canaan Partners Lawrence Klein - Head of Business Development & Strategy CRISPR Therapeutics
•How do the exciting approvals in the past 18 months impact opportunities for other companies in the space?
•What are the more mature partnering opportunities for therapy and new technology?
•What are the outcomes to expect in the coming year?
•How will the recent developments in market access affect gene and cell therapy?
Brinda BalakrishnanGVP, Corporate & Business Development
Jim BowenExecutive Director, Corporate Alliances, Penn Center for Innovation
University of Pennsylvania
Nina KjellsonGeneral Partner
Lawrence KleinHead of Business Development & Strategy
11:20 am - 11:35 am Biotech Spotlight | Rare DiseaseBrian Fenton - Chief Business Officer Translate Bio
11:35 am - 11:50 am Biotech Spotlight
11:50 am - 12:20 pm Panel: Current Trends in Strategic Corporate VenturesScott Carter - Of Counsel Morrison Foerster Markus Goebel - Managing Director Novartis Venture Fund Hongbo Lu - Partner Lilly Asia Ventures Michael Martin - Head of Takeda Ventures Takeda
•What are the advantages of having corporate VCs in your capital structure?
•What are the benefits of a big pharma company having a venture arm?
•Are there differing approaches in looking for opportunities between corporate and traditional VCs?
Markus GoebelManaging Director
Novartis Venture Fund
Lilly Asia Ventures
Michael MartinHead of Takeda Ventures
Scott CarterOf Counsel
12:20 pm - 12:35 pm Biotech Spotlight
12:35 pm - 12:50 pm Biotech Spotlight
9:50 am - 12:50 pm 1:1 Partnering
12:50 pm - 1:50 pm Lunch
1:50 pm - 2:20 pm Panel: The Promising Frontiers in Neuroscience DevelopmentsLeon Chen - Venture Partner OrbiMed Don Frail - SVP, Research, External Science & Innovation Allergan Elaine Jones - VP, Venture Capital Pfizer Michal Preminger - Executive Director, Harvard University Office of Technology Development Harvard Medical School
•What is the emerging science in the space?
•Where are the most interesting opportunities?
•What are the transactional challenges to overcome?
Leon ChenVenture Partner
Don FrailSVP, Research, External Science & Innovation
Elaine JonesVP, Venture Capital
Michal PremingerExecutive Director, Harvard University Office of Technology Development
Harvard Medical School
2:20 pm - 2:35 pm Biotech Spotlight
2:35 pm - 2:50 pm Biotech Spotlight
2:50 pm - 3:20 pm Panel: Creative Strategies in Biopharma FundingTimothy Herpin - Chief Business Officer Caribou Biosciences Neena Kadaba - Director, Science Quark Venture Ari Nowacek - Principal ARCH Ventures Ioannis Sapountzis - US Head, Business Development & Licensing and Specialty Pharma Boehringer Ingelheim Lesley Stolz - Head, JLABS Bay Area Johnson & Johnson Innovation
•What are some creative deals done including co-development or co-promotional rights for small pharma?
•What are some lessons from unconventional deals that have taken place in the past couple of years?
•How is the biopharma funding landscape evolving?
•How can small pharma take advantage od the current funding environment?
Timothy HerpinChief Business Officer
Neena KadabaDirector, Science
Ioannis SapountzisUS Head, Business Development & Licensing and Specialty Pharma
Lesley StolzHead, JLABS Bay Area
Johnson & Johnson Innovation
3:20 pm - 3:35 pm Biotech Spotlight
3:35 pm - 3:50 pm Biotech Spotlight
3:50 pm - 4:20 pm Afternoon Refreshment Break
4:20 pm - 4:35 pm Biotech Spotlight
4:35 pm - 4:50 pm Biotech Spotlight
4:50 pm - 5:20 pm Deal Spotlight: Ex-US Insights: Perspectives from Big & Small PharmaSimon Bateman - Executive Director, Business Development & Licensing, Alliance Management Novartis Oncology Lauren Kaskiel - Alliance Management & New Project Planning Leader Spark Therapeutics
As Novartis gained ex-US rights to Spark’s Luxturna, the first gene therapy to gain FDA approval earlier this year, Simon Bateman and Lauren Kaskiel will share lessons learned.
Simon BatemanExecutive Director, Business Development & Licensing, Alliance Management
Lauren KaskielAlliance Management & New Project Planning Leader